FTC Warns 25 Healthcare Marketers and Lead Generators Over Deceptive Advertising Practices

The Federal Trade Commission is warning 25 healthcare marketers and lead generation companies about potentially deceptive advertising and unlawful telemarketing practices, emphasizing the legal risks associated with misleading consumers about health insurance coverage, costs, and benefits.

In an Oct. 29 announcement, the FTC said it is sending warning letters to companies that advertise Affordable Care Act Marketplace insurance and other healthcare products, including limited benefit plans and medical discount programs. The agency expects to send additional letters on a rolling basis.

The initiative highlights the FTC’s continued scrutiny of lead generation, consumer solicitation, and third-party marketing practices, particularly where advertising claims or telemarketing activities may mislead consumers.

FTC Identifies Deceptive Healthcare Marketing Practices

The FTC’s warning letter template identifies several categories of potentially unlawful conduct under Section 5 of the FTC Act, which prohibits unfair or deceptive acts or practices in commerce.

According to the agency, problematic marketing claims may include:

• Misrepresenting the benefits or limitations of healthcare products, including insurance coverage.
• Advertising limited benefit or medical discount plans as comprehensive health insurance.
• Providing misleading information about healthcare plan costs.
• Falsely promising cash rewards, rebates, free offers or other incentives for enrollment.

The FTC said these concerns reflect consumer complaints and the agency’s previous enforcement experience involving healthcare marketers and lead generators.

“Making healthcare more transparent and affordable is a top priority for the FTC,” said Christopher Mufarrige, director of the FTC’s Bureau of Consumer Protection.

Mufarrige said the agency would continue monitoring the market and pursuing companies that unlawfully advertise healthcare products.

Telemarketing and Lead Generation Face Additional Scrutiny

Beyond misleading advertising, the warning letters address telemarketing practices and the use of consumer information in healthcare lead generation.

The FTC specifically references the Telemarketing Sales Rule (TSR), which restricts certain prerecorded sales calls and prohibits calls to numbers on the National Do Not Call Registry unless an applicable exception exists.

The letters also address requirements for express, informed consent before charging consumers for products.

Another area of concern involves the FTC’s Rule on Impersonation of Government and Business. The rule prohibits falsely representing a company as a government agency or legitimate business, or misleading consumers about government or business affiliation, endorsement or sponsorship.

For healthcare marketers, this includes claims suggesting that an insurance product is associated with the Department of Health and Human Services, an established insurance carrier or an Affordable Care Act program when that relationship does not exist.

The FTC warned that violations of applicable rules can result in civil penalties of up to $53,088 per violation, with individual unlawful calls, advertisements or misrepresentations potentially constituting separate violations. Other consequences may include injunctions, consumer refunds and additional court-ordered relief.

Previous FTC Cases Highlight Financial Consequences

The warning letters reference several previous enforcement actions involving healthcare marketing and lead generation.

In August 2025, the FTC announced that Assurance IQ and MediaAlpha agreed to pay a combined $145 million to resolve allegations involving deceptive healthcare marketing practices.

The agency alleged that Assurance IQ misled consumers about healthcare coverage through telemarketing, while MediaAlpha used deceptive advertisements and websites to generate consumer leads that were sold to healthcare telemarketers.

The FTC also cited its 2024 judgment against Simple Health Plans, which imposed a $195 million judgment and permanent restrictions on telemarketing and healthcare product sales following allegations involving the deceptive marketing of limited benefit and medical discount programs.

More recently, the agency pursued litigation against Top Healthcare Options Insurance Agency and Innovative Partners over alleged misrepresentations involving healthcare coverage and, in the Innovative Partners case, government and insurance carrier impersonation. Both cases were identified as ongoing in the FTC’s warning letters.

Together, the cases illustrate how deceptive marketing practices can lead to substantial financial judgments, operational restrictions, and consumer restitution.

What the Warning Letters Mean for Lead Generators and Compliance Teams

Although the current initiative specifically targets healthcare marketing, the FTC’s emphasis on advertising accuracy, telemarketing compliance, and third-party oversight has broader relevance for companies that rely on consumer lead generation and outbound communications.

For receivables management organizations, the letters offer a reminder of the regulatory risks associated with inaccurate representations, consent management and outsourced consumer contact operations.

The FTC encourages recipients to review advertising and promotional practices across websites, paid advertisements, social media, sales communications and third-party distribution channels.

For compliance professionals overseeing comparable consumer-facing operations, relevant review areas include the accuracy of marketing representations, documentation of required consumer consent, compliance with applicable calling restrictions, and oversight of external vendors.

The letters also underscore the importance of reviewing third-party conduct rather than limiting compliance assessments to internally managed communications.

Importantly, the FTC explicitly states that receiving a warning letter does not constitute a finding or allegation of wrongdoing against the recipient.

The agency has not announced enforcement actions against the 25 recipients as part of this initiative. Instead, the letters serve as compliance warnings informed by prior FTC investigations and litigation.

The FTC said it will continue monitoring healthcare marketing and lead generation activities and pursue enforcement action when warranted.